

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

RM-1 [Mouse prostate carcinoma]

RRID:CVCL_B459

Type: Cell Line

Proper Citation

Ubigen Cat# YC-C049, RRID:CVCL_B459

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_B459

Proper Citation: Ubigen Cat# YC-C049, RRID:CVCL_B459

Description: Cell line RM-1 [Mouse prostate carcinoma] is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Male

Disease: Carcinoma of the mouse prostate gland

Defining Citation: [PMID:7538321](#)

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: RM-1 [Mouse prostate carcinoma]

Synonyms: RM1

Cross References: BTO:BTO_0003780, ATCC:CRL-3310, CCRID:3101MOUTCM14, CLS:305168, Ubigen:YC-C049, Wikidata:Q54950629

ID: CVCL_B459

Vendor: Ubigen

Catalog Number: YC-C049

Record Creation Time: 20250130T072720+0000

Record Last Update: 20260905T184140+0000

Ratings and Alerts

No rating or validation information has been found for RM-1 [Mouse prostate carcinoma].

No alerts have been found for RM-1 [Mouse prostate carcinoma].

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 34 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Fan X, et al. (2026) CRISPR-Cas9-Loaded Theranostic Liposomes for Enhancing Radiosensitization of Prostate Cancer through POLD4 Gene Editing under Real-Time MRI Monitoring. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e19704.

Li H, et al. (2026) YEATS2 promotes DNA repair and induces anoikis resistance by enhancing chromatin accessibility to drive prostate cancer metastasis. Oncogene, 45(11), 971.

Zhang H, et al. (2026) ROS Cascade-Amplified Polymeric Nanosystem Exhibiting Multi-Pathway Induction of Immunogenic Cell Death and Chemotherapeutic Efficacy in Tumor. Advanced healthcare materials, 15(25), e71279.

Nasr MM, et al. (2026) PRDM16 Regulates Prostate Cancer Cell Dormancy and Prevents Bone Metastatic Outgrowth. Cancer research, 86(3), 604.

Brevi A, et al. (2026) Intercepting YAP Activation in Prostate Cancer Blocks Neuroendocrine Progression. Cancer research, 86(12), 2860.

Gao L, et al. (2026) Targeting PKMYT1 enhances antitumor immune responses to PD-L1 blockade in castration-resistant prostate cancer. Journal for immunotherapy of cancer, 14(1).

Jiao Y, et al. (2026) A Plasmonic "Lid-Off" Nanoplatfrom for Spatiotemporally Controlled PA/NIR-II Dual-Modal Imaging and Cuproptosis-Based Synergistic Photothermal and Chemodynamic Therapy. Small (Weinheim an der Bergstrasse, Germany), 22(37), e73776.

Ding J, et al. (2026) CDC20 promotes prostate cancer progression via modulating c-MYC and PI3K-AKT signaling. iScience, 29(7), 116409.

Liu S, et al. (2026) Betulinic acid induces lysosome-dependent death in prostate cancer by targeting DDX5. Phytomedicine : international journal of phytotherapy and phytopharmacology, 155, 158143.

Wang Y, et al. (2026) GUTK induces apoptosis in reactivating quiescent prostate cancer cells via Aurora A-mediated stabilization of SOD2. iScience, 29(5), 115739.

- Du Q, et al. (2026) Gasdermin D antagonizes immunosuppression in prostate cancer by inducing LAMC2 degradation to block M2 macrophage polarization. *Journal for immunotherapy of cancer*, 14(5).
- Di J, et al. (2026) Sequential nanocatalytic therapy and lysosomal dysfunction for overcoming castration-resistant prostate cancer. *Bioactive materials*, 64, 232.
- Wang Q, et al. (2025) AR+TREM2+ macrophage induced pathogenic immunosuppression promotes prostate cancer progression. *Nature communications*, 16(1), 6964.
- Sun F, et al. (2025) CAMK1D activates AMPK/PINK1/Parkin-dependent mitophagy to promote enzalutamide resistance in prostate cancer. *Cell death & disease*, 17(1), 113.
- Johnson CS, et al. (2025) Targeted Deletion of Cxcl1 in MSCs Regulates Osteogenesis and Suppresses Bone-Metastatic Prostate Cancer. *Molecular cancer research : MCR*, 23(8), 739.
- Salloom RJ, et al. (2025) Synergistic effects of HO-1 inhibition and chemotherapy on tumor proliferation and immune infiltration: An in vitro and in vivo approach to enhancing prostate cancer treatment. *Translational oncology*, 54, 102339.
- Mei S, et al. (2025) Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis. *Molecular cancer research : MCR*, 23(7), 653.
- Deng B, et al. (2025) PDGFC facilitates enzalutamide resistance in prostate cancer through activation of the Rap1-MAPK pathway. *Journal of cancer research and clinical oncology*, 151(10), 267.
- Duhan V, et al. (2025) FcR??-Dependent NK Cell Licensing through CD244 Promotes Antitumor Immunity. *Cancer immunology research*, 13(12), 2075.
- Zhao T, et al. (2025) Derepressing nuclear pyruvate dehydrogenase induces therapeutic cancer cell reprogramming. *Cell metabolism*, 37(8), 1667.